Horizon Therapeutics Public Company Investor Relations Material

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. It markets IMMUNOCAL to physicians and healthcare professionals in the fields of pediatrics, rheumatology, orthopedics/spine, internal medicine/primary care, physical medicine and rehabilitation/pain management, neurology/neurosurgery, and sports medicine; and IMMUNOTEC to doctors and healthcare professionals in the field of gastroenterology. The company was formerly known as Horizon Pharma Plc and changed its name to Horizon Therapeutics Public Limited Company in April 2019